In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)

This publication has 10 references indexed in Scilit:

• Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx™)
  Bioorganic & Medicinal Chemistry Letters, 2000
• Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration
  Inflammation Research, 1999
• SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor
  Bioorganic & Medicinal Chemistry Letters, 1999
• The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
  Bioorganic & Medicinal Chemistry Letters, 1999
• COX-2 inhibitors
  The Lancet, 1999
• 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors
  Bioorganic & Medicinal Chemistry Letters, 1998
• Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor
  British Journal of Pharmacology, 1997
• Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)
  Journal of Medicinal Chemistry, 1997
• A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
  Inflammation Research, 1996
• Kinetic Studies on Rifampicin
  Chemotherapy, 1971